Sutimlimab (BIVV009) for the adult participants with cold agglutinin disease (CAD) who have completed Phase 3 studies (CARDINAL or CADENZA) in Japan

Trial Identifier: LTS17352
Sponsor: Sanofi
Start Date: November 2021
Primary Completion Date: November 2022
Study Completion Date: November 2022
Condition: Cold Agglutinin Disease (CAD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Japan Ishikawa, Japan, 920-8530
Japan Kanagawa, Japan, 259-1193
Japan Osaka, Japan, 565-0871
Japan Saitama, Japan, 350-0495
Japan Tokyo, Japan, 113-8431